Výsledky vyhledávání - D Britten

Upřesnit hledání
  1. 1
    Targeting ErbB receptor signaling: A pan-ErbB approach to cancer

    Targeting ErbB receptor signaling: A pan-ErbB approach to cancer Autor Carolyn D. Britten

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

    G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Autor Nancy L. R. Bucher, Carolyn D. Britten

    Vydáno 2008
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Automatic trial eligibility surveillance based on unstructured clinical data

    Automatic trial eligibility surveillance based on unstructured clinical data Autor Stéphane M. Meystre, Paul M. Heider, Young-Jun Kim, Daniel Aruch, Carolyn D. Britten

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy

    Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy Autor Tara Arvedson, Julie M. Bailis, Carolyn D. Britten, Matthias Klinger, Dirk Nagorsen, Angela Coxon, Jackson G. Egen, Flavius Martin

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    An overview of the CellML API and its implementation

    An overview of the CellML API and its implementation Autor Andrew K. Miller, Justin Marsh, Adam Reeve, Alan Garny, Randall D. Britten, Matt Halstead, Jonathan Cooper, David Nickerson, Poul F Nielsen

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

    Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study Autor Carolyn D. Britten, Antoinette S. Gomes, Zev A. Wainberg, David Elashoff, Rafael G. Amado, Xin Yan, Ronald W. Busuttil, Dennis J. Slamon, Richard S. Finn

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer

    Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer Autor Antonio Giordano, Yueying Liu, Kent Armeson, Yeonhee Park, Maya Ridinger, Mark G. Erlander, James M. Reuben, Carolyn D. Britten, Christiana S. Kappler, Elizabeth S. Yeh, Stephen P. Ethier

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Autor Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O’Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian W. Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors

    A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors Autor Carolyn D. Britten, Elizabeth Garrett‐Mayer, Steven Chin, Keisuke Shirai, Besim Öğretmen, Tricia A. Bentz, Alan Brisendine, Kate Anderton, Susan Cusack, Lynn W. Maines, Yan Zhuang, Charles D. Smith, Melanie B. Thomas

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

    Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors Autor Pasi A. Jänne, David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon, Feng Guo, Steven Wong, Jane Liang, Stephen P. Letrent, Robert Millham, Ian Taylor, S. Gail Eckhardt, Jan H.M. Schellens

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

    First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors Autor Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn D. Britten, Karen S. Jacks, Monica Mita, Vali Papadimitrakopoulou, Tim Pluard, Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, Cristina Fernandez‐Ibarra, Hong Lü, Stuart Bailey, Sandra Chica, Udai Banerji

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    CellML metadata standards, associated tools and repositories

    CellML metadata standards, associated tools and repositories Autor Daniel Beard, Randall D. Britten, Michael T. Cooling, Alan Garny, Matt Halstead, Peter Hunter, James R. Lawson, Catherine M. Lloyd, Justin Marsh, Andrew Miller, David Nickerson, Poul M. F. Nielsen, Taishin Nomura, Shankar Subramanium, Sarala Wimalaratne, Tommy Yu

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

    A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer Autor Zev A. Wainberg, María Alsina, Heloisa P. Soares, Irene Braña, Carolyn D. Britten, Gianluca Del Conte, Patrick I. Ezeh, Brett E. Houk, Kenneth A. Kern, Stephen Leong, Nazima Pathan, Kristen J. Pierce, Lillian L. Siu, Jennifer Vermette, Josep Tabernero

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

    Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of meta... Autor Marcus Smith Noel, Eileen M. O’Reilly, Brian M. Wolpin, David P. Ryan, Andrea J. Bullock, Carolyn D. Britten, David C. Linehan, Brian A. Belt, Eric Gamelin, Bishu Ganguly, Donghua Yin, Tenshang Joh, Ira Jacobs, Carrie Turich Taylor, Maeve A. Lowery

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

    Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer Autor Edward B. Garon, Heather R. Christofk, Wylie Hosmer, Carolyn D. Britten, Agnes Y. Bahng, Matthew Crabtree, Candice Sun Hong, Naeimeh Kamranpour, Sharon Pitts, Fairooz F. Kabbinavar, Cecil Patel, Erika von Euw, Alexander Black, Evangelos D. Michelakis, Steven M. Dubinett, Dennis J. Slamon

    Vydáno 2014
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

    A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected... Autor Philippe L. Bédard, Josep Tabernero, Filip Janků, Zev A. Wainberg, Luis Paz‐Ares, Johan Vansteenkiste, Eric Van Cutsem, José Manuel Pérez-García, Anastasios Stathis, Carolyn D. Britten, Ngocdiep T. Le, Kirsten Carter, David Demanse, Dénes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

    Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer Autor Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett‐Mayer, Colleen Cloud, Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. Thomas, Chrystal M. Paulos, Andres Μ. Salazar, Michael I. Nishimura, Mark P. Rubinstein, Zihai Li, David J. Cole

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Autor Manish R. Patel, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Carolyn D. Britten, Luc Dirix, Keun‐Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B. Gelb, Junyuan Xiong, Galit Rosen, James L. Gulley, Andrea B. Apolo

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Treatment Failure in a UK Malaria Patient Harboring Genetically Variant <i>Plasmodium falciparum</i> From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine

    Treatment Failure in a UK Malaria Patient Harboring Genetically Variant <i>Plasmodium falciparum</i> From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrin... Autor Donelly A. van Schalkwyk, Sade Pratt, Debbie Nolder, Lindsay B. Stewart, Helen Liddy, Julian Muwanguzi-Karugaba, Khalid B. Beshir, D Britten, Emma L. Victory, Claire Rogers, James Millard, Michael Brown, Laura Nabarro, Andrew Taylor, Bernadette C. Young, Peter L. Chiodini, Colin J. Sutherland

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study Autor Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin M. Chin, James L. Gulley

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: